Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update

References

• Mallbris L, Davies J, Glasebrook A, et al. Molecular insights into fully human and humanized monoclonal antibodies: what are the differences and should dermatologists care? The Journal of Clinical and Aesthetic Dermatology. 2016;9(7):13–15.
   PubMedGoogle Scholar
• Statement on sarcoidosis. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS board of directors and by the ERS executive committee, february 1999.. Am J Respir Crit Care Med. 1999;160(2):736–755.
   PubMedGoogle Scholar
• Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164(10):1885–1889.
   PubMed Web of Science ®Google Scholar
• Moller DR, Rybicki BA, Hamzeh NY, et al. Genetic, Immunologic, and Environmental Basis of Sarcoidosis. Ann Am Thorac Soc. 2017;14(6):S429–S436.
   PubMedGoogle Scholar
• Li CW, Tao RJ, Zou DF, et al. Pulmonary sarcoidosis with and without extrapulmonary involvement: a cross-sectional and observational study in China. BMJ Open. 2018;8(2):e018865.
   PubMed Web of Science ®Google Scholar
• Pietinalho A, Hiraga Y, Hosoda Y, et al. The frequency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study. Sarcoidosis. 1995;12(1):61–67.
   PubMedGoogle Scholar
• Pietinalho A, Ohmichi M, Hiraga Y, et al. The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan. A comparative analysis of 571 Finnish and 686 Japanese patients. Sarcoidosis Vasc Diffuse Lung Dis. 1996;13(2):159–166.
   PubMed Web of Science ®Google Scholar
• Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med. 1997;336(17):1224–1234.
   PubMed Web of Science ®Google Scholar
• Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. american thoracic society/european respiratory society/world association of sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):149–173.
   PubMed Web of Science ®Google Scholar
• Tavee J, Culver D. Nonorgan manifestations of sarcoidosis. Curr Opin Pulm Med. 2019;25(5):533–538.
   PubMed Web of Science ®Google Scholar
• Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and detection of sarcoidosis. an official american thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(8):e26–e51.
   PubMed Web of Science ®Google Scholar
• Valeyre D, Prasse A, Nunes H, et al. Sarcoidosis. The Lancet. 2014;383(9923):1155–1167.
   PubMed Web of Science ®Google Scholar
• Rahaghi FF, Baughman RP, Saketkoo LA, et al. Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. Eur Respir Rev. 2020;29(155):190146.
   Web of Science ®Google Scholar
• Baughman RP, Scholand MB, Rahaghi FF. Clinical phenotyping: role in treatment isions in sarcoidosis. Eur Respir Rev. 2020;29(155):190145.
   Web of Science ®Google Scholar
• Baughman RP, Wells A. Advanced sarcoidosis. Current Opinion in Pulmonary Medicine. 2019;25(5):497–504.
   PubMed Web of Science ®Google Scholar
• Gibson GJ, Prescott RJ, Muers MF, et al. British thoracic society sarcoidosis study: effects of long term corticosteroid treatment.. Thorax. 2020;29(155):190146–190147.
   Google Scholar
• Baughman RP, Nunes H, Sweiss NJ, et al. Established and experimental medical therapy of pulmonary sarcoidosis. European Respiratory Journal. 2013;41(6):1424–1438.
   PubMed Web of Science ®Google Scholar
• McKinzie BP, Bullington WM, Mazur JE, et al. Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. The American Journal of the Medical Sciences. 2006;23(1):1–4.
   Google Scholar
• Baughman RP, Lower EE. Steroids for sarcoidosis: how much and for how long? Respiratory Medicine. 2018;138:S5–S6.
   Web of Science ®Google Scholar
• Beegle SH, Barba K, Gobunsuy R, et al. Current and emerging pharmacological treatments for sarcoidosis: a review.. Drug Design, Development and Therapy. 2013;7:325–338.
   PubMed Web of Science ®Google Scholar
• Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respiratory Medicine. 2010;104(5):717–723.
   PubMed Web of Science ®Google Scholar
• Judson MA. Corticosteroids in Sarcoidosis. Rheum Dis Clin North Am. 2016;42(1):119–135.
   PubMed Web of Science ®Google Scholar
• Khan NA, Donatelli CV, Tonelli AR, et al. Toxicity risk from glucocorticoids in sarcoidosis patients. Respiratory Medicine. 2017;132:9–14.
   PubMed Web of Science ®Google Scholar
• Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Annals of the Rheumatic Diseases. 2009;68(7):1119–1124.
   PubMed Web of Science ®Google Scholar
• Broos CE, Poell LHC, Looman CWN, et al. No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis. Respiratory Medicine. 2018;138:S31–S37.
   Web of Science ®Google Scholar
• Baughman RP, Grutters JC. New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. The Lancet Respiratory Medicine. 2011;18(8):1306–1316.
   Google Scholar
• Vorselaars ADM, Cremers JP, Grutters JC, et al. Cytotoxic agents in sarcoidosis: which one should we choose? Current Opinion in Pulmonary Medicine. 2014;20(5):479–487.
   PubMed Web of Science ®Google Scholar
• Vorselaars AD, van Moorsel CH, Deneer VH, et al. Current therapy in sarcoidosis, the role of existing drugs and future medicine. <![CDATA[Inflammation & Allergy-Drug Targets]]>. 2013;12(6):369–377.
   PubMedGoogle Scholar
• Moor CC, Kahlmann V, Culver DA, et al. Comprehensive care for patients with sarcoidosis. J Clin Med. 2020;9(2):390. .
   Web of Science ®Google Scholar
• Ma Y, Gal A, Koss M. Reprint of: the pathology of pulmonary sarcoidosis: update. Seminars in Diagnostic Pathology. 2018;35(5):324–333.
   PubMed Web of Science ®Google Scholar
• Broos CE, van Nimwegen M, Hoogsteden HC, et al. Granuloma formation in pulmonary sarcoidosis. Frontiers in Immunology. 2014;20:437.
   Google Scholar
• Chen ES, Moller DR. Etiology of sarcoidosis. Clinics in Chest Medicine. 2008;29(3):365–377.
   PubMed Web of Science ®Google Scholar
• Saidha S, Sotirchos ES, Eckstein C. Etiology of sarcoidosis: does infection play a role? The Yale Journal of Biology and Medicine. 2012;85(1):133–141.
   PubMedGoogle Scholar
• Gerke AK, Hunninghake G. The immunology of sarcoidosis. Clinics in Chest Medicine. 2020;82(3):612–621.
   Google Scholar
• Iannuzzi MC. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA. 2018;35(5):324–333.
   Google Scholar
• Facco M, Cabrelle A, Teramo A, et al. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax. 2011;66(2):144–150.
   PubMed Web of Science ®Google Scholar
• Oswald-Richter KA, Drake WP. The etiologic role of infectious antigens in sarcoidosis pathogenesis. Seminars in Respiratory and Critical Care Medicine. 1965;6(3):303–306.
   Google Scholar
• Oswald-Richter KA, Beachboard DC, Seeley EH, et al. Dual analysis for mycobacteria and propionibacteria in sarcoidosis BAL. Journal of Clinical Immunology. 2012;32(5):1129–1140.
   PubMed Web of Science ®Google Scholar
• Drake WP, Pei Z, Pride DT, et al. Molecular analysis of sarcoidosis tissues for mycobacterium species DNA. Emerging Infectious Diseases. 2002;8(11):1334–1341.
   PubMed Web of Science ®Google Scholar
• Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004 15;170(12):1324–1330.
   PubMed Web of Science ®Google Scholar
• Iannuzzi MC. Genetics of sarcoidosis. Semin Respir Crit Care Med. 2007;28(1):15–21.
   PubMed Web of Science ®Google Scholar
• Barnard J, Rose C, Newman L, et al. Job and industry classifications associated with sarcoidosis in A case-control etiologic study of sarcoidosis (ACCESS). J Occup Environ Med. 2005;47(3):226–234.
   PubMed Web of Science ®Google Scholar
• Eishi Y, Suga M, Ishige I, et al. Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. J Clin Microbiol. 2002;40(1):198–204.
   PubMed Web of Science ®Google Scholar
• Goto H, Usui Y, Umazume A, et al. as a possible pathogen of granuloma in patients with ocular sarcoidosis. Br J Ophthalmol. 2017;101(11):1510–1513.
   PubMed Web of Science ®Google Scholar
• Hiramatsu J, Kataoka M, Nakata Y, et al. Propionibacterium acnes DNA detected in bronchoalveolar lavage cells from patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20(3):197–203.
   PubMed Web of Science ®Google Scholar
• Yang G, Eishi Y, Raza A, et al. Propionibacterium acnes-associated neurosarcoidosis: a case report with review of the literature. Neuropathology. 2018;38(2):159–164.
   PubMed Web of Science ®Google Scholar
• Chen ES, Wahlström J, Song Z, et al. T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol. 2008;181(12):8784–8796.
   PubMed Web of Science ®Google Scholar
• Oswald-Richter KA, Culver DA, Hawkins C, et al. Cellular responses to mycobacterial antigens are present in bronchoalveolar lavage fluid used in the diagnosis of sarcoidosis. Infect Immun. 2009;77(9):3740–3748.
   PubMed Web of Science ®Google Scholar
• Oswald-Richter K, Sato H, Hajizadeh R, et al. Mycobacterial ESAT-6 and katG are recognized by sarcoidosis CD4+ T cells when presented by the American sarcoidosis susceptibility allele, DRB1*1101. J Clin Immunol. 2010;30(1):157–166.
   PubMed Web of Science ®Google Scholar
• Nikoskelainen J, Hannuksela M, Palva T. Antibodies to Epstein-Barr virus and some other herpesviruses in patients with sarcoidosis, pulmonary tuberculosis and erythema nodosum. Scand J Infect Dis. 1974;6(3):209–216.
   PubMed Web of Science ®Google Scholar
• Prezant DJ, Dhala A, Goldstein A, et al. The incidence, prevalence, and severity of sarcoidosis in new york city firefighters. Chest. 1999;116(5):1183–1193.
   PubMed Web of Science ®Google Scholar
• Kern DG, Neill MA, Wrenn DS, et al. Investigation of a unique time-space cluster of sarcoidosis in firefighters. Am Rev Respir Dis. 1993;148(4 Pt 1):974–980.
   PubMedGoogle Scholar
• Deubelbeiss U, Gemperli A, Schindler C, et al. Prevalence of sarcoidosis in Switzerland is associated with environmental factors. Eur Respir J. 2010;35(5):1088–1097.
   PubMed Web of Science ®Google Scholar
• Huizar I, Malur A, Midgette YA, et al. Novel murine model of chronic granulomatous lung inflammation elicited by carbon nanotubes. Am J Respir Cell Mol Biol. 2011;45(4):858–866.
   PubMed Web of Science ®Google Scholar
• Bunte K, Beikler T. Th17 Cells and the IL-23/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases. Int J Mol Sci. 2019;20(14): 3394.
   PubMed Web of Science ®Google Scholar
• Moller DR, Forman JD, Liu MC, et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol. 1996;156(12):4952–4960.
   PubMed Web of Science ®Google Scholar
• Shigehara K, Shijubo N, Ohmichi M, et al. IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. J Immunol. 2001;166(1):642–649.
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Hocking RJ, Atkins CJ, et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24(2):179–189.
   PubMed Web of Science ®Google Scholar
• Zissel G, Müller-Quernheim J. Cellular players in the immunopathogenesis of sarcoidosis. Clin Chest Med. 2015;36(4):549–560.
   PubMed Web of Science ®Google Scholar
• Bayer AL, Pugliese A, Malek TR, et al. 2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation. Immunol Res. 2013;57(1–3):197–209.
   PubMed Web of Science ®Google Scholar
• Nelson BH, Willerford DM. Biology of the interleukin-2 receptor. Adv Immunol. 1998;70:1–81.
   PubMed Web of Science ®Google Scholar
• Kumar A, Moreau JL, Gibert M, et al. Internalization of interleukin 2 (IL-2) by high affinity IL-2 receptors is required for the growth of IL-2-dependent T cell lines. J Immunol. 1987;139(11):3680–3684.
   PubMed Web of Science ®Google Scholar
• Vanmaris RMM, Rijkers GT. Biological role of the soluble interleukin-2 receptor in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(2):122–129.
   PubMed Web of Science ®Google Scholar
• Vorselaars AD, van Moorsel CH, Zanen P, et al. ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy. Respir Med. 2015;109(2):279–285.
   PubMed Web of Science ®Google Scholar
• Ogata-Suetsugu S, Hamada N, Takayama K, et al. The clinical value of serum soluble interleukin-2 receptor in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(1):41–47.
   PubMed Web of Science ®Google Scholar
• Lawrence EC, Berger MB, Brousseau KP, et al. Elevated serum levels of soluble interleukin-2 receptors in active pulmonary sarcoidosis: relative specificity and association with hypercalcemia. Sarcoidosis. 1987;4(2):87–93.
   PubMedGoogle Scholar
• Keicho N, Kitamura K, Takaku F, et al. Serum concentration of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis. Chest. 1990;98(5):1125–1129.
   PubMed Web of Science ®Google Scholar
• Ina Y, Takada K, Sato T, et al. Soluble interleukin 2 receptors in patients with sarcoidosis. Possible Origin Chest. 1992;102(4):1128–1133.
   Google Scholar
• Müller-Quernheim J, Pfeifer S, Strausz J, et al. Correlation of clinical and immunologic parameters of the inflammatory activity of pulmonary sarcoidosis. Am Rev Respir Dis. 1991;144(6):1322–1329.
   PubMed Web of Science ®Google Scholar
• Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126(6):1121–1133.
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441(7090):235–238.
   PubMed Web of Science ®Google Scholar
• Zissel G, Homolka J, Schlaak J, et al. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. Am J Respir Crit Care Med. 1996;154(3 Pt 1):713–719.
   PubMed Web of Science ®Google Scholar
• Korn T, Oukka M, Kuchroo V, et al. Th17 cells: effector T cells with inflammatory properties. Semin Immunol. 2007;19(6):362–371.
   PubMed Web of Science ®Google Scholar
• Weinberg I, Vasiliev L, Gotsman I. Anti-dsDNA antibodies in sarcoidosis. Semin Arthritis Rheum. 2000;29(5):328–331.
   PubMed Web of Science ®Google Scholar
• Kobak S, Yilmaz H, Sever F, et al. The prevalence of antinuclear antibodies in patients with sarcoidosis. Autoimmune Dis. 2014;2014:351852.
   PubMedGoogle Scholar
• Ueda-Hayakawa I, Tanimura H, Osawa M, et al. Elevated serum BAFF levels in patients with sarcoidosis: association with disease activity. Rheumatology (Oxford). 2013;52(9):1658–1666.
   PubMed Web of Science ®Google Scholar
• Fischer A, Nothnagel M, Franke A, et al. Association of inflammatory bowel disease risk loci with sarcoidosis, and its acute and chronic subphenotypes. Eur Respir J. 2011;37(3):610–616.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Judson MA, Teirstein A, et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM. 2006;99(5):307–315.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Nagai S, Balter M, et al. Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(1):56–64.
   PubMed Web of Science ®Google Scholar
• Johns CJ, Michele TM. The clinical management of sarcoidosis. A 50-year experience at the johns hopkins hospital. Medicine (Baltimore). 1999;78(2):65–111.
   PubMed Web of Science ®Google Scholar
• Saketkoo LA, Baughman RP. Biologic therapies in the treatment of sarcoidosis. Expert Rev Clin Immunol. 2016;12(8):817–825.
   PubMed Web of Science ®Google Scholar
• Taflin C, Miyara M, Nochy D, et al. FoxP3+ regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions. Am J Pathol. 2009;174(2):497–508.
   PubMed Web of Science ®Google Scholar
• Miyara M, Amoura Z, Parizot C, et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med. 2006;203(2):359–370.
   PubMed Web of Science ®Google Scholar
• Rappl G, Pabst S, Riemann D, et al. Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation. Clin Immunol. 2011;140(1):71–83.
   PubMed Web of Science ®Google Scholar
• Oswald-Richter KA, Richmond BW, Braun NA, et al. Reversal of global CD4+ subset dysfunction is associated with spontaneous clinical resolution of pulmonary sarcoidosis. J Immunol. 2013;190(11):5446–5453.
   PubMed Web of Science ®Google Scholar
• Prasse A, Zissel G, Lützen N, et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med. 2010;182(4):540–548.
   PubMed Web of Science ®Google Scholar
• Prokop S, Heppner FL, Goebel HH, et al. M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis. Am J Pathol. 2011;178(3):1279–1286.
   PubMed Web of Science ®Google Scholar
• Kunkel SL, Lukacs NW, Strieter RM, et al. Th1 and Th2 responses regulate experimental lung granuloma development. Sarcoidosis Vasc Diffuse Lung Dis. 1996;13(2):120–128.
   PubMed Web of Science ®Google Scholar
• Chen ES, Song Z, Willett MH, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med. 2010;181(4):360–373.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795–802.
   PubMed Web of Science ®Google Scholar
• Sweiss NJ, Noth I, Mirsaeidi M, et al. Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(1):46–54.
   PubMed Web of Science ®Google Scholar
• Tuchinda C, Wong HK. Etanercept for chronic progressive cutaneous sarcoidosis. J Drugs Dermatol. 2006;5(6):538–540.
   PubMedGoogle Scholar
• Sweiss NJ, Lower EE, Mirsaeidi M, et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J. 2014;43(5):1525–1528.
   PubMed Web of Science ®Google Scholar
• Sharp M, Donnelly SC, Moller DR. Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents. Respir Med X. 2019;1:100004.
   PubMedGoogle Scholar
• Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(2):119–127.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Judson MA, AU W. The indications for the treatment of sarcoidosis: wells law. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34:280–282.
   PubMed Web of Science ®Google Scholar
• Wells AU. Sarcoidosis: a benign disease or a culture of neglect? Respir Med. 2018;144S:S1–S2.
   PubMedGoogle Scholar
• Swigris JJ, Olson AL, Huie TJ, et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med. 2011;183(11):1524–1530.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Winget DB, Bowen EH, et al. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14(2):154–158.
   PubMed Web of Science ®Google Scholar
• Hu X, Carmona EM, Yi ES, et al. Causes of death in patients with chronic sarcoidosis.. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33(3):275–280.
   PubMed Web of Science ®Google Scholar
• Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations.. Archives of Pathology & Laboratory Medicine. 1995;119(2):167–172.
   PubMed Web of Science ®Google Scholar
• Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61(11):980–985.
   PubMed Web of Science ®Google Scholar
• Judson MA, Chaudhry H, Louis A, et al. The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis. Respiratory Medicine. 2015;109(4):526–531.
   PubMed Web of Science ®Google Scholar
• Brito-Zeron P, Perez-Alvarez R, Pallares L, et al. Sarcoidosis: an update on current pharmacotherapy options and future directions. Expert Opinion on Pharmacotherapy. 2016;17(18):2431–2448. .
   PubMed Web of Science ®Google Scholar
• Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2000;17(1):60–66.
   PubMed Web of Science ®Google Scholar
• Cremers JP, Drent M, Bast A, et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Current Opinion in Pulmonary Medicine. 2013;19(5):545–561.
   PubMed Web of Science ®Google Scholar
• Vorselaars ADM, Wuyts WA, Vorselaars VMM, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest. 2013;144(3):805–812.
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Ainslie GM, Bateman ED, et al. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 1999;16(1):87–92.
   PubMed Web of Science ®Google Scholar
• Majithia V, Sanders s, Harisdangkul V, et al. Successful treatment of sarcoidosis with leflunomide. Rheumatology (Oxford). 2003;42(5):700–702.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2004;21(1):43–48.
   PubMed Web of Science ®Google Scholar
• Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. European Respiratory Journal. 2011;38(5):1145–1150.
   PubMed Web of Science ®Google Scholar
• Brill A-K, Ott SR, Geiser T. Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study. Respiration. 2013;86(5):376–383.
   PubMed Web of Science ®Google Scholar
• Androdias G, Maillet D, Marignier R, et al. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology. 2011;76(13):1168–1172.
   PubMed Web of Science ®Google Scholar
• Zaidi AA, DeVita MV, Michelis MF, et al. Mycophenolate mofetil as a steroid-sparing agent in sarcoid-associated renal disease. Clinical Nephrology. 2015;83 (2015)(1):41–44.
   Web of Science ®Google Scholar
• Bitoun S, Bouvry D, Borie R, et al. Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil. Neurology. 2016;87(24):2517–2521.
   PubMed Web of Science ®Google Scholar
• Drent M, Cremers JP, sen TL, et al. Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):91–107.
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay D, Judson M. Emerging and potential treatment options for sarcoidosis. Expert Opin Orphan Drugs. 2018;6(1):17–33.
   Web of Science ®Google Scholar
• Baughman RP, Drent M, Kavuru M. Infliximab for the therapy of chronic sarcoidosis, Baughman RP, Drent M, Kavuru M et al.: infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. . American Journal of Respiratory and Critical Care Medicine. 2006;174(7):795–802.
   PubMed Web of Science ®Google Scholar
• Jamilloux Y, Cohen-Aubart F, Chapelon-Abric C, et al. Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients. Semin Arthritis Rheum. 2017;47(2):288–294.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Bradshaw MJ, Stern BJ, et al. Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series. Neurology. 2017;89(20):2092–2100.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Judson MA, Lower EE, et al. Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2016;32(4):289–295.
   PubMed Web of Science ®Google Scholar
• Crommelin HA, van der Burg LM, Vorselaars ADM, et al. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. Respiratory Medicine. 2016;115:72–77.
   PubMed Web of Science ®Google Scholar
• Pariser RJ, Paul J, Hirano S, et al. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. Journal of the American Academy of Dermatology. 2013;68(5):765–773.
   PubMed Web of Science ®Google Scholar
• Harper LJ, McCarthy M, Ribeiro Neto ML, et al. Infliximab for refractory cardiac sarcoidosis. Am J Cardiol. 2019;124(10):1630–1635.
   PubMed Web of Science ®Google Scholar
• Zella S, Kneiphof J, Haghikia A, et al. Successful therapy with rituximab in three patients with probable neurosarcoidosis. Therapeutic Advances in Neurological Disorders. 2018;11:1756286418805732.
   Web of Science ®Google Scholar
• Cinetto F, Compagno N, Scarpa R, et al. Rituximab in refractory sarcoidosis: a single centre experience. Clinical and Molecular Allergy. 2015;13(1):19.
   PubMedGoogle Scholar
• Krause ML, Cooper LT, Chareonthaitawee P, et al. Successful use of rituximab in refractory cardiac sarcoidosis. Rheumatology (Oxford). 2016;55(1):189–191.
   PubMed Web of Science ®Google Scholar
• Lower EE, Baughman RP, Kaufman AH. Rituximab for refractory granulomatous eye disease.. Clinical Ophthalmology (Auckland, N.Z.). 2012;6:1613–1618.
   PubMedGoogle Scholar
• Judson MA, Baughman RP, Costabel U, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. European Respiratory Journal. 2014;44(5):1296–1307.
   PubMed Web of Science ®Google Scholar
• El Jammal T, Jamilloux Y, Gerfaud-Valentin M, et al. <p>Refractory Sarcoidosis: a Review. <![cdata[therapeutics and Clinical Risk Management]]>. 2020;16:323–345.
   PubMed Web of Science ®Google Scholar
• Chopra A, Nautiyal A, Kalkanis A, et al. Drug-Induced Sarcoidosis-Like Reactions. Chest. 2018;154(3):664–677.
   PubMed Web of Science ®Google Scholar
• Mitoma H, Horiuchi T, Tsukamoto H, et al. Molecular mechanisms of action of anti-TNF-α agents – comparison among therapeutic TNF-α antagonists. Cytokine. 2018;101:56–63.
   PubMed Web of Science ®Google Scholar
• Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31(4):299–316.
   PubMed Web of Science ®Google Scholar
• Marques IB, Giovannoni G, Marta M. Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanercept. BMC Neurol. 2014;14(1):237.
   PubMedGoogle Scholar
• Wijnen PA, Cremers JP, Nelemans PJ, et al. Association of the TNF- G-308A polymorphism with TNF-inhibitor response in sarcoidosis. Eur Respir J. 2014;43(6):1730–1739.
   PubMed Web of Science ®Google Scholar
• Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 american college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care & Research. 2012 ;64(5):625–639.
   PubMed Web of Science ®Google Scholar
• Furst DE, Keystone EC, So AK, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: table 1. Ann Rheum Dis. 2013;72(Suppl 2):22–34.
   Google Scholar
• Baughman RP, Lower EE. Infliximab for refractory sarcoidosis.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2001;18(1):70–74.
   PubMed Web of Science ®Google Scholar
• Yee AMF, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti–tumor necrosis factor-α therapy. Annals of Internal Medicine. 2001;135(1):27–31.
   PubMed Web of Science ®Google Scholar
• Rossman MD, Newman LS, Baughman RP, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2006;23(3):201–208.
   PubMed Web of Science ®Google Scholar
• Hostettler KE, Studler U, Tamm M, et al. Long-term treatment with infliximab in patients with sarcoidosis. Respiration. 2012;83(3):218–224.
   PubMed Web of Science ®Google Scholar
• Vorselaars ADM, Crommelin HA, Deneer VHM, et al. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. European Respiratory Journal. 2015;46(1):175–185.
   PubMed Web of Science ®Google Scholar
• Aguiar M, Marçal N, Mendes AC, et al. Infliximab no tratamento da sarcoidose - Experiência de um hospital central. Rev Port Pneumol. 2011;17(2):85–93.
   PubMed Web of Science ®Google Scholar
• Crouser ED, Lozanski G, Fox CC, et al. The CD4 + lymphopenic sarcoidosis phenotype is highly responsive to anti-tumor necrosis factor-α therapy. Chest. 2010;137(6):1432–1435.
   PubMed Web of Science ®Google Scholar
• Jounieaux F, Chapelon C, Valeyre D, et al. Infliximab et sarcoïdose chronique. L’expérience française à propos de 31 cas. Revue des Maladies Respiratoires. 2010;27(7):685–692.
   PubMed Web of Science ®Google Scholar
• Keijsers RG, Verzijlbergen EJ, van den Bosch JM, et al. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis.. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(2):123–129.
   PubMed Web of Science ®Google Scholar
• Pritchard C. Tumour necrosis factor inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. . Annals of the Rheumatic Diseases. 2004;63(3):318–320.
   PubMed Web of Science ®Google Scholar
• Saleh S, Ghodsian S, Yakimova V, et al. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respiratory Medicine. 2006;100(11):2053–2059.
   PubMed Web of Science ®Google Scholar
• Vorselaars AD, Verwoerd A, van Moorsel CH, et al. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. European Respiratory Journal. 2014;43(2):602–609.
   PubMed Web of Science ®Google Scholar
• Russell E, Luk F, Manocha S, et al. Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy. Seminars in Arthritis and Rheumatism. 2013;43(1):119–124.
   PubMed Web of Science ®Google Scholar
• Sweiss NJ, Barnathan ES, Lo K, et al. C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2010;27(1):49–56.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Shipley R, Desai S, et al. Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest. 1999;16(1):526–535.
   Google Scholar
• Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. European Respiratory Journal. 2013;86(5):376–383.
   Google Scholar
• Adler BL, Wang CJ, Bui T-L, et al. Anti-tumor necrosis factor agents in sarcoidosis: a systematic review of efficacy and safety. Semin Arthritis Rheum. 2011;76(13):1093–1104.
   Google Scholar
• Baughman RP. Tumor necrosis factor inhibition in treating sarcoidosis: the American experience. Revista Portuguesa de. 2006;Pneumologia 174(7):S47–S50.
   Google Scholar
• Panselinas E, Rodgers JK, Judson MA. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology. 2016;115(4):72–77.
   Google Scholar
• Chapelon-Abric C, Saadoun D, Biard L, et al. Long-term outcome of infliximab in severe chronic and refractory systemic sarcoidosis: a report of 16 cases.. Clinical and Experimental Rheumatology. 2015;33(4):509–515.
   PubMed Web of Science ®Google Scholar
• Stagaki E, Mountford WK, Lackland DT, et al. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest. 2009;135(2):468–476.
   PubMed Web of Science ®Google Scholar
• Heidelberger V, Ingen-Housz-Oro S, Marquet A, et al. Efficacy and tolerance of anti–tumor necrosis factor α agents in cutaneous sarcoidosis. JAMA Dermatology. 2012;6(7):681–685.
   Google Scholar
• Sweiss NJ, Welsch MJ, Curran JJ, et al. Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis & Rheumatism. 2020;16(5):323–345.
   Google Scholar
• Sodhi M, Pearson K, White ES, et al. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respiratory Medicine. 2009;103(2):268–273.
   PubMed Web of Science ®Google Scholar
• Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology. 2009;72(4):337–340.
   PubMed Web of Science ®Google Scholar
• Santos E, Shaunak S, Renowden S, et al. Treatment of refractory neurosarcoidosis with Infliximab. Journal of Neurology, Neurosurgery & Psychiatry. 2014;43(6):1730–1739.
   Google Scholar
• Riancho-Zarrabeitia L, Delgado-Alvarado M, Riancho J, et al. Anti-TNF-α therapy in the management of severe neurosarcoidosis: a report of five cases from a single centre and literature review.. Clin Exp Rheumatol. 2014;32(2):275–284.
   PubMed Web of Science ®Google Scholar
• Fritz D, Timmermans WMC, van Laar JAM, et al. Infliximab treatment in pathology-confirmed neurosarcoidosis. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e847.
   PubMed Web of Science ®Google Scholar
• Cohen Aubart F, Bouvry D, Galanaud D, et al. Long-term outcomes of refractory neurosarcoidosis treated with infliximab. Journal of Neurology. 2013;43(1):891–897.
   Google Scholar
• Riancho-Zarrabeitia L, Calvo-Río V, Blanco R, et al. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: multicenter study of 17 patients. Semin Arthritis Rheum. 2009;136(2):526–535.
   Google Scholar
• Baughman RP, Bradley DA, Lower EE. Infliximab in chronic ocular inflammation. IntJournal of Clinical Pharmacology and Therapeutics. 2005;43(1):7–11.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, Ingledue R, et al. Management of ocular sarcoidosis.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2012;29(1):26–33.
   PubMed Web of Science ®Google Scholar
• Vallet H, Seve P, Biard L, et al. Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: a Multicenter Study From the French Uveitis Network. Arthritis Rheumatol. 2008;31(6):1189–1196.
   Google Scholar
• Fabiani C, Vitale A, Rigante D, et al. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Clin Rheumatol. 2007;13(2):407–415.
   Google Scholar
• Mann DL, McMurray JJV, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2009;14(4):522–528.
   Google Scholar
• Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial.. Circulation. 2003;107(25):3133–3140.
   PubMed Web of Science ®Google Scholar
• Uthman I, Touma Z, Khoury M. Cardiac sarcoidosis responding to monotherapy with infliximab. Clinical Rheumatology. 2007;26(11):2001–2003.
   PubMed Web of Science ®Google Scholar
• Barnabe C, McMeekin J, Howarth A, et al. Successful treatment of cardiac sarcoidosis with infliximab.. The Journal of Rheumatology. 2008;35(8):1686–1687.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Lower EE, Li H, et al. Clinical characteristics of patients with bone sarcoidosis. Semin Arthritis Rheum. 2017;47(1):143–148.
   PubMed Web of Science ®Google Scholar
• Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest. 2005;127(3):1064–1071.
   PubMed Web of Science ®Google Scholar
• Tavee JO, Karwa K, Ahmed Z, et al. Sarcoidosis-associated small fiber neuropathy in a large cohort: clinical aspects and response to IVIG and anti-TNF alpha treatment. Respiratory Medicine. 2013;41:135–138.
   Google Scholar
• Hoitsma E, Faber CG, Reulen JPH, et al. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab.. Circulation. 2004;109(13):1594–1602.
   Google Scholar
• Elfferich MD, Nelemans PJ, Ponds RW, et al. Everyday cognitive failure in sarcoidosis: the prevalence and the effect of Anti-TNF-α treatment. Respiration. 2010;80(3):212–219.
   PubMed Web of Science ®Google Scholar
• Judson MA. Quality of life in sarcoidosis. Semin Respir Crit Care Med. 2017;38(4):546–558.
   PubMed Web of Science ®Google Scholar
• Obi ON. Health-related quality of life in sarcoidosis. Semin Respir Crit Care Med. 2020;41(5):716–732.
   PubMedGoogle Scholar
• Maneiro JR, Salgado E, Gomez-Reino JJ, et al. Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review. Seminars in Arthritis and Rheumatism. 2012;42(1):89–103.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them.. Sarcoidosis, Vasculitis, and Diffuse Lung diseases : Official Journal of WASOG. 2012;42(1):76–89.
   Google Scholar
• Schimmelpennink MC, Vorselaars ADM, Veltkamp M, et al. Quantification of pulmonary disease activity in sarcoidosis measured with 18F-FDG PET/CT: sUVmax versus total lung glycolysis. EJNMMI Research. 2008;25(2):54.
   Google Scholar
• Muers MF, Middleton WG, Gibson GJ, et al. A simple radiographic scoring method for monitoring pulmonary sarcoidosis: relations between radiographic scores, dyspnoea grade and respiratory function in the british thoracic society study of long-term corticosteroid treatment.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 1997;14(1):46–56.
   PubMed Web of Science ®Google Scholar
• Judson MA, Baughman RP, Costabel U, et al. The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial. Respiratory Medicine. 2014;108(1):189–194.
   PubMed Web of Science ®Google Scholar
• Wijnen PA, Nelemans PJ, Verschakelen JA, et al. The role of tumor necrosis factor alpha G-308A polymorphisms in the course of pulmonary sarcoidosis. Tissue Antigens. 2010;75(3):262–268.
   PubMedGoogle Scholar
• Seitzer U, Swider C, Stüber F, et al. Tumour necrosis factor alpha promoter gene polymorphism in sarcoidosis. Cytokine. 1997;9(10):787–790.
   PubMed Web of Science ®Google Scholar
• Lower EE, Sturdivant M, Grate L, et al. Use of third-line therapies in advanced sarcoidosis. Clin Exp Rheumatol. 2019;38(5):834–840.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Features of sarcoidosis associated with chronic disease.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2015;31(4):275–281.
   PubMed Web of Science ®Google Scholar
• Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest. 1997;111(3):623–631.
   PubMed Web of Science ®Google Scholar
• Alok N, Zia H, Ajmal K, et al. Experience of sarcoidosis and factors predicting relapse at a tertiary care institute in North India. Indian J Rheumatol. 2019;14(4):265–270.
   Web of Science ®Google Scholar
• Crommelin HA, Vorselaars AD, van Moorsel CH, et al. Anti-TNF therapeutics for the treatment of sarcoidosis. Immunotherapy. 2014;6(10):1127–1143.
   PubMed Web of Science ®Google Scholar
• Judson MA. Advances in the diagnosis and treatment of sarcoidosis. F1000Prime Reports. 2014;6:89.
   PubMedGoogle Scholar
• Milman N, Graudal N, Loft A, et al. Effect of the TNF-α inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. The Clinical Respiratory Journal. 2012;6(4):238–247.
   PubMed Web of Science ®Google Scholar
• Erckens RJ, Mostard RL, Wijnen PA, et al. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2012;250(5):713–720.
   PubMed Web of Science ®Google Scholar
• Rosenthal DG, Parwani P, Murray TO, et al. Long-term corticosteroid-sparing immunosuppression for cardiac sarcoidosis. J Am Heart Assoc. 2019;8(18):e010952.
   PubMed Web of Science ®Google Scholar
• Goto H, Zako M, Namba K, et al. Adalimumab in active and inactive, non-infectious uveitis: global results from the VISUAL I and VISUAL II Trials. Ocul Immunol Inflamm. 2019;27(1):40–50.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Sota J, Rigante D, et al. Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. Clinical Rheumatology. 2018;37(10):2805–2809.
   PubMed Web of Science ®Google Scholar
• Bitossi A, Bettiol A, Silvestri E, et al. Adalimumab accounts for long-term control of noninfectious uveitis also in the absence of concomitant DMARD treatment: a multicenter retrospective study. Mediators of Inflammation. 2019;2019:1623847.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Emmi G, et al. Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. Clinical Rheumatology. 2019;38(1):63–70.
   PubMed Web of Science ®Google Scholar
• Miller CT, Sweiss NJ, Lu Y. FDG PET/CT evidence of effective treatment of cardiac sarcoidosis with adalimumab. Clinical Nuclear Medicine. 2016;41(5):417–418.
   PubMed Web of Science ®Google Scholar
• Patel SR. Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report. J Med Case Rep. 2009;3(1):8573.
   PubMedGoogle Scholar
• Hasni SA, Kunz D, Finzel K, et al. Osseous sarcoidosis treated with tumor necrosis factor-inhibitors: case report and review of the literature. Spine (Phila Pa 1976). 2010;35(18):E904–7.
   PubMed Web of Science ®Google Scholar
• Kamphuis LS, Lam-Tse W-K, Dik WA, et al. Efficacy of adalimumab in chronically active and symptomatic patients with sarcoidosis. American Journal of Respiratory and Critical Care Medicine. 2011;184(10):1214–1216.
   PubMed Web of Science ®Google Scholar
• Alawneh D, Al-Shyoukh A, Edrees A. TNF inhibitor treating osseous sarcoidosis and dactylitis: case and literature review. Clinical Rheumatology. 2020;39(7):2219–2222.
   PubMed Web of Science ®Google Scholar
• Banse C, Bisson-Vaivre B-V, Kozyreff-Meurice M, et al. No impact of tumor necrosis-factor antagonists on the joint manifestations of sarcoidosis. International Journal of General Medicine. 2013;6:605–611.
   PubMedGoogle Scholar
• Lower EE, Sturdivant M, Baughman RP. Presence of onconeural antibodies in sarcoidosis patients with parasarcoidosis syndrome.. Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(4):254–260.
   PubMed Web of Science ®Google Scholar
• Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003;124(1):177–185.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, Bradley DA, et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest. 2005;128(2):1062–2047.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121(5):1088–1094.
   PubMed Web of Science ®Google Scholar
• Storch I, Rosoff L, Katz S. Sarcoidosis and inflammatory bowel disease. Journal of Clinical Gastroenterology. 2001;33(4):345.
   PubMed Web of Science ®Google Scholar
• Brunner J, Sergi C, Müller T, et al. Juvenile sarcoidosis presenting as Crohn’s disease. European Journal of Pediatrics. 2006;165(6):398–401.
   PubMed Web of Science ®Google Scholar
• Bhamra K, Stevens R. Pulmonary sarcoidosis following etanercept treatment.. Case Reports in Rheumatology. 2012;2012:724013.
   PubMedGoogle Scholar
• Clementine RR, Lyman J, Zakem J, et al. Tumor necrosis factor-alpha antagonist-induced sarcoidosis. JCR: Journal of Clinical Rheumatology. 2010;16(6):274–279.
   PubMed Web of Science ®Google Scholar
• ock A, Van Assche G, Vermeire S, et al. Sarcoidosis-like lesions: another paradoxical reaction to Anti-TNF Therapy? J Crohns Colitis. 2017;11(3):378–383.
   PubMed Web of Science ®Google Scholar
• Cathcart S, Sami N, Elewski B. Sarcoidosis as an adverse effect of tumor necrosis factor inhibitors.. Journal of Drugs in Dermatology : JDD. 2012;11(5):609–612.
   PubMed Web of Science ®Google Scholar
• Suzuki J, Goto H. Uveitis associated with sarcoidosis exacerbated by etanercept therapy. Japanese Journal of Ophthalmology. 2009;53(4):439–440.
   PubMed Web of Science ®Google Scholar
• Sawahata M, Sigiyama Y, Yamasawa H, et al. Sarcoidosis during etanercept treatment for rheumatoid arthritis in women with a history of bilateral oophorectomy.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2016;33(2):178–181.
   PubMed Web of Science ®Google Scholar
• Cuchacovich R, Hagan J, Khan T, et al. Tumor necrosis factor-alpha (TNF-α)-blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): case report and review of the literature. Clinical Rheumatology. 2011;30(1):133–137.
   PubMed Web of Science ®Google Scholar
• Wendling D, Nueffer JP. Muscular sarcoidosis under anti-TNF treatment in ankylosing spondylitis. Joint Bone Spine. 2018;85(6):769.
   PubMed Web of Science ®Google Scholar
• Berrios I, Jun-O’Connell A, Ghiran S, et al. A case of neurosarcoidosis secondary to treatment of etanercept and review of the literature.. BMJ Case Reports. 2015;2015:2015.
   Google Scholar
• Durel CA, Feurer E, Pialat JB, et al. Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis. BMC Neurol. 2013;13:212.
   PubMed Web of Science ®Google Scholar
• Unterstell N, Bressan AL, Serpa LA, et al. Systemic sarcoidosis induced by etanercept: first Brazilian case report. An Bras Dermatol. 2013;88(6 Suppl 1):197–199.
   PubMed Web of Science ®Google Scholar
• Vigne C, Tebib J-G, Pacheco Y, et al. Sarcoidosis: an underestimated and potentially severe side effect of anti-TNF-alpha therapy. Joint Bone Spine. 2013;80(1):104–107.
   PubMed Web of Science ®Google Scholar
• Watrin A, Royer M, Legrand E, et al. Hypercalcémie majeure révélatrice d’une sarcoïdose induite par étanercept. Revue des Maladies Respiratoires. 2014;31(3):255–258.
   PubMedGoogle Scholar
• Yokoe I, Haraoka H, Yonamine T, et al. [Case Report; Long-term treatment with etanercept induced systemic sarcoidosis in a patient with rheumatoid arthritis]. Nihon Naika Gakkai Zasshi. 2015;104(4):769–774.
   PubMedGoogle Scholar
• Daien CI, Monnier A, Claudepierre P, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford). 2009;48(8):883–886.
   PubMed Web of Science ®Google Scholar
• Tong D, Manolios N, Howe G, et al. New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication. Internal Medicine Journal. 2012;42(1):89–94.
   PubMed Web of Science ®Google Scholar
• Perez-De-Lis M, Retamozo S, Flores-Chavez A, et al. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opinion on Drug Safety. 2017;16(11):1255–1271.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, Soto M-J, et al. Autoimmune diseases induced by TNF-targeted therapies. Best Practice & Research Clinical Rheumatology. 2008;22(5):847–861.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M, et al. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. The American Journal of Medicine. 2011;124(5):386–394.
   PubMed Web of Science ®Google Scholar
• Toussirot E, Bernard C, Bossert M. Safety of the use of anti-IL17A treatment in a patient with certolizumab-induced sarcoidosis.. Clinical and Experimental Rheumatology. 2019;37(2):344–345.
   PubMed Web of Science ®Google Scholar
• Koda K, Toyoshima M, Nozue T, et al. Systemic sarcoidosis associated with certolizumab pegol treatment for rheumatoid arthritis: a case report and review of the literature. Internal Medicine. 2020;59(16):2015–2021.
   PubMed Web of Science ®Google Scholar
• Syed H, Ascoli C, Linssen CF, et al. Infection prevention in sarcoidosis:proposal for vaccination and prophylactic therapy. Sarcoidosis Vasculitis Diffuse Lung Dis. 2020;37(2):87–98.
   PubMed Web of Science ®Google Scholar
• Vorselaars ADM, Hijdra D, van Moorsel CHM, et al. Antinuclear antibodies do not predict anti-infliximab antibody induction in sarcoidosis. Journal of the American Academy of Dermatology. 2013;69(2):312–314.
   PubMed Web of Science ®Google Scholar
• Veltkamp M, Drent M, Baughman RP. Infliximab or biosimilars in sarcoidosis; to switch or not to switch? Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2016;32(4):280–283.
   PubMed Web of Science ®Google Scholar
• Al Sulais E, AlAmeel T. Biosimilars to antitumor necrosis factor agents in inflammatory bowel disease.. Biologics : Targets & Therapy. 2020;14:1–11.
   PubMedGoogle Scholar
• Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–1620.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76(2):355–363.
   PubMed Web of Science ®Google Scholar
• Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–2316.
   PubMed Web of Science ®Google Scholar
• Riller Q, Cotteret C, Junot H, et al. Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment. Journal of Neurology. 2019;266(5):1073–1078.
   PubMed Web of Science ®Google Scholar
• Schimmelpennink MC, Vorselaars ADM, van Beek FT, et al. Efficacy and safety of infliximab biosimilar. Inflectra® in Severe Sarcoidosis. Respiratory Medicine. 2018 ;138:S7–S13.
   Google Scholar
• Xue L, van Bilsen K, Schreurs MWJ, et al. Are patients at risk for recurrent disease activity after switching from remicade to remsima? An observational study. Frontiers in Medicine. 2020;7:418.
   PubMed Web of Science ®Google Scholar
• Korsten P, Strohmayer K, Baughman RP, et al. Refractory pulmonary sarcoidosis - proposal of a definition and recommendations for the diagnostic and therapeutic approach. . Clinical Pulmonary Medicine. 2016;23(2):67–75.
   PubMedGoogle Scholar
• Baughman RP, Sweiss N, Keijsers R, et al. Repository corticotropin for chronic pulmonary sarcoidosis. Lung. 2017;195(3):313–322.
   PubMed Web of Science ®Google Scholar
• Chopra I, Qin Y, Kranyak J, et al. Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records. Therapeutic Advances in Respiratory Disease. 2019;13:1753466619888127.
   Web of Science ®Google Scholar
• Drake WP, Richmond BW, Oswald-Richter K, et al. Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis.. Sarcoidosis, Vasculitis, and Diffuse Lung diseases : Official Journal of WASOG. 2012;250(5):713–720.
   Google Scholar
• Drake WP, Oswald-Richter K, Richmond BW, et al. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. JAMA Dermatology. 2012;250(5):713–720.
   Google Scholar
• Richmond BW, Richter K, King LE, et al. Resolution of chronic ocular sarcoidosis with antimycobacterial therapy. Case Rep Intern Med. 2014;1(2):5042.
   PubMedGoogle Scholar
• Hunninghake GW, Crystal RG. Mechanisms of hypergammaglobulinemia in pulmonary sarcoidosis. Site of increased antibody production and role of T lymphocytes. Journal of Clinical Investigation. 2011;124(5):86–92.
   Google Scholar
• Baughman RP, Hurtubise PE. Systemic immune response of patients with active pulmonary sarcoidosis.. Clinical and Experimental Immunology. 2018;138(3):S7–S13.
   Google Scholar
• Daniele RP, McMillan LJ, Dauber JH, et al. Immune complexes in sarcoidosis: a correlation with activity and duration of disease. Chest. 1978;74(3):261–264.
   PubMed Web of Science ®Google Scholar
• Dall’Aglio PP, Pesci A, Bertorelli G, et al. Study of immune complexes in bronchoalveolar lavage fluids. Respiration. 1988;54(Suppl 1):36–41.
   PubMedGoogle Scholar
• Lee N-S, Barber L, Akula SM, et al. Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis. Clinical and Vaccine Immunology. 2016;23(2):67–75.
   Google Scholar
• Saussine A, Tazi A, Feuillet S, et al. Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels. PLoS One. 2013;30(3):e43588.
   Google Scholar
• Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435–445.
   PubMed Web of Science ®Google Scholar
• US National Library of Medicine. RITUXAN – rituximab 2020 [updated March 24, 2020; [cited 2020 September 10]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563
   Google Scholar
• Puechal X, Gottenberg JE, Berthelot JM, et al. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: results from the autoimmunity and rituximab registry. Arthritis Care & Research. 2012;64(3):331–339.
   PubMed Web of Science ®Google Scholar
• Galimberti F, Fernandez AP. Sarcoidosis following successful treatment of pemphigus vulgaris with rituximab: a rituximab-induced reaction further supporting B-cell contribution to sarcoidosis pathogenesis? Clinical and Experimental Dermatology. 2016;41(4):413–416.
   PubMed Web of Science ®Google Scholar
• Beccastrini E, Vannozzi L, Bacherini D, et al. Successful treatment of ocular sarcoidosis with rituximab.. Ocular Immunology and Inflammation. 2013;21(3):244–246.
   PubMed Web of Science ®Google Scholar
• Belkhou A, Younsi R, El Bouchti I, et al. Rituximab as a treatment alternative in sarcoidosis. Joint Bone Spine. 2008;75(4):511–512.
   PubMed Web of Science ®Google Scholar
• Dasilva V, Breuil V, Chevallier P, et al. Relapse of severe sarcoidosis with an uncommon peritoneal location after TNFα blockade. Efficacy of rituximab, report of a single case. Joint Bone Spine. 2010;77(1):82–83.
   PubMed Web of Science ®Google Scholar
• Bomprezzi R, Pati S, Chansakul C, et al. A case of neurosarcoidosis successfully treated with rituximab. Neurology. 2010;75(6):568–570.
   PubMed Web of Science ®Google Scholar
• Earle B, Wolf DS, Ramsay ES. Novel use of rituximab in treatment of refractory neurosarcoidosis in an 11-Year-Old Girl. J Clin Rheumatol. 2018;25(6):e101-e103.
   Web of Science ®Google Scholar
• Sawaya R, Radwan W. Sarcoidosis associated with neuromyelitis optica. Journal of Clinical Neuroscience. 2013;20(8):1156–1158.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Fleischmann RM, Furst DE, et al. Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 Years. J Rheumatol. 2015;42(10):1761–1766.
   PubMed Web of Science ®Google Scholar
• Pescitelli L, Emmi G, Tripo L, et al. Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: an uncommon adverse effect? Eur J Dermatol. 2017;27(6):667–668.
   PubMed Web of Science ®Google Scholar
• Vesely NC, Thomas RM, Longo MI. Scar sarcoidosis following rituximab therapy. Dermatol Ther. 2020 ;33(6):e13693.
   PubMed Web of Science ®Google Scholar
• Miller MA, Bass HE. Effect of Acthar-c (ACTH) in sarcoidosis. Ann Inter Med. 1952;37(4):776–784.
   PubMed Web of Science ®Google Scholar
• Salomon A, Appel B, Collins SF, et al. Sarcoidosis: pulmonary and skin studies before and after ACTH and cortisone therapy. Diseases of the Chest. 1956;29(3):277–291.
   PubMedGoogle Scholar
• Baughman RP, Barney JB, O’Hare L, et al. A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients. Respiratory Medicine. 2016;110:66–72.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Lower EE, Li H, et al. Sarcoidosis patient with lupus pernio and infliximab-induced myositis: response to Acthar gel.. Respiratory Medicine Case Reports. 2016;17:5–7.
   PubMed Web of Science ®Google Scholar
• Montero-Melendez T. ACTH: the forgotten therapy. Seminars in Immunology. 2015;27(3):216–226.
   PubMed Web of Science ®Google Scholar
• Ross AP, Ben-Zacharia A, Harris C, et al. Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone. Frontiers in Neurology. 2013;4:21.
   PubMed Web of Science ®Google Scholar
• Taylor A, Namba K. In vitro induction of CD25 + CD4 + regulatory T cells by the neuropeptide alpha-melanocyte stimulating hormone (α-MSH). Immunol Cell Biol. 2001;79(4):358–367.
   PubMed Web of Science ®Google Scholar
• Namba K, Kitaichi N, Nishida T, et al. Induction of regulatory T cells by the immunomodulating cytokines alpha-melanocyte-stimulating hormone and transforming growth factor-beta2.. J Leukoc Biol. 2002;72(5):946–952.
   PubMed Web of Science ®Google Scholar
• Rahaghi FF, Sweiss NJ, Saketkoo LA, et al. Management of repository corticotrophin injection therapy for pulmonary sarcoidosis: a Delphi study. Eur Respir Rev. 2020;29(155):190147.
   Web of Science ®Google Scholar
• Zhou T, Casanova N, Pouladi N, et al. Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature. Sci Rep. 2017;7(1):4237.
   PubMedGoogle Scholar
• Rosenbach M. Janus kinase inhibitors offer promise for a new era of targeted treatment for granulomatous disorders. . Journal of the American Academy of Dermatology. 2020;82(3):e91–e92.
   PubMed Web of Science ®Google Scholar
• Wang A, Singh K, Ibrahim W, et al. The promise of jak inhibitors for treatment of sarcoidosis and other inflammatory disorders with macrophage activation: a review of the Literature. Yale J Biol Med. 2020;93(1):187–195.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, Pasadhika S, Crouser ED, et al. Hypothesis: sarcoidosis is a STAT1-mediated disease. Clin Immunol. 2009;132(2):174–183.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66(1):311–328.
   PubMedGoogle Scholar
• O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368(2):161–170.
   PubMed Web of Science ®Google Scholar
• Kisseleva T, Bhattacharya S, Braunstein J, et al. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002;285(1–2):1–24.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, Hessellund A, Phan I, et al. The expression of STAT-1 and phosphorylated STAT-1 in conjunctival granulomas. Ocul Immunol Inflamm. 2010;18(4):261–264.
   PubMed Web of Science ®Google Scholar
• Damsky W, Thakral D, Emeagwali N, et al. Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med. 2018;379(26):2540–2546. .
   PubMed Web of Science ®Google Scholar
• Damsky W, Thakral D, McGeary MK, et al. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. J Am Acad Dermatol. 2020;82(3):612-621.
   Web of Science ®Google Scholar
• Gadina M, Johnson C, Schwartz D, et al. Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs. Journal of Leukocyte Biology. 2018;104(3):499–514.
   PubMed Web of Science ®Google Scholar
• Westhovens R. Clinical efficacy of new JAK inhibitors under development. Just more of the same? Rheumatology (Oxford). 2019;58(Suppl Supplement_1):i27–i33.
   PubMedGoogle Scholar
• Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014;120(4):513–520.
   PubMed Web of Science ®Google Scholar
• Rotenberg C, Besnard V, Brillet PY, et al. Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia. Eur Respir J. 2018;52(6):1801482.
   PubMed Web of Science ®Google Scholar
• Wei JJ, Kallenbach LR, Kreider M, et al. Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera. JAAD Case Reports. 2019;5(4):360–361.
   PubMedGoogle Scholar
• Levraut M, Martis N, Viau P, et al. Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib. Ann Rheum Dis. 2019 ;78(11):1606–1607.
   PubMed Web of Science ®Google Scholar
• Damsky W, Young BD, Sloan B, et al. Treatment of multiorgan sarcoidosis with tofacitinib. ACR Open Rheumatology. 2020;2(2):106–109.
   PubMedGoogle Scholar
• Sejournet L, Kodjikian L, Grange L, et al. Resolution of ocular and mediastinal sarcoidosis after Janus kinase inhibitor therapy for concomitant rheumatoid arthritis.. Clinical and Experimental Rheumatology. 2020 June 30.
   PubMed Web of Science ®Google Scholar
• Damsky W, Thakral D, McGeary MK, et al. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. J Am Acad Dermatol. 2020;82(3):612–621.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Tofacitinib hypothesis-generating, pilot study for corticosteroid-dependent sarcoidosis 2019 [cited 2020 Sept 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT03793439
   Google Scholar
• ClinicalTrials.gov. Open-label trial of tofacitinib in cutaneous sarcoidosis and granuloma annulare 2019 [cited 2020 Sept 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT03910543
   Google Scholar
• Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(10):1755–1766.
   PubMed Web of Science ®Google Scholar
• Strand V, Ahadieh S, French J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Research & Therapy. 2018;11(17):362.
   Google Scholar
• Winthrop KL, Wouters AG, Choy EH, et al. The Safety and Immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase ii trial. Arthritis & Rheumatology. 2017;69(10):1969–1977.
   PubMed Web of Science ®Google Scholar
• Sahashi K, Ina Y, Takada K, et al. Significance of interleukin 6 in patients with sarcoidosis. Chest. 1994;106(1):156–160 .
   PubMed Web of Science ®Google Scholar
• Takizawa H, Satoh M, Okazaki H, et al. Increased IL-6 and IL-8 in bronchoalveolar lavage fluids (BALF) from patients with sarcoidosis: correlation with the clinical parameters. Clin Exp Immunol. 1997;107(1):175–181.
   PubMed Web of Science ®Google Scholar
• Denisova O, Egorova K, Chernogoryuk G. TNF-α, IL-8, IL-6 levels in serum of sarcoidosis patients with different clinical course. Eur Respir J. 2013;42:3787.
   Google Scholar
• Chazal T, Costopoulos M, Maillart E, et al. The cerebrospinal fluid CD4/CD8 ratio and interleukin-6 and -10 levels in neurosarcoidosis: a multicenter. comparative study. Eur J Neurol: pragmatic; 2019.
   Google Scholar
• Chen ES, Moller DR. Sarcoidosis—scientific progress and clinical challenges. Nature Reviews Rheumatology. 2011;7(8):457–467.
   PubMed Web of Science ®Google Scholar
• Dienz O, Rincon M. The effects of IL-6 on CD4 T cell responses. Clin Immunol. 2009;130(1):27–33.
   PubMed Web of Science ®Google Scholar
• Terabe F, Fujimoto M, Serada S, et al. Comparative analysis of the effects of anti-IL-6 receptor mAb and anti-TNF mAb treatment on CD4+ T-cell responses in murine colitis. Inflamm Bowel Dis. 2018;104(3):491–502.
   Google Scholar
• Song S-NJ, Yoshizaki K. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opinion on Drug Metabolism & Toxicology. 2018;52(6):307–316.
   Google Scholar
• Raimondo MG, Biggioggero M, Crotti C, et al. Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib. Annals of the Rheumatic Diseases. 2019;78:1593–1603.
   Web of Science ®Google Scholar
• Bae S-C, Lee YH. Vergleichbare Wirksamkeit und Verträglichkeit von Sarilumab 150 und 200 mg bei Patienten mit aktiver rheumatoider Arthritis. Zeitschrift für Rheumatologie. 2018;77(5):421–428.
   PubMedGoogle Scholar
• Kim GW, Lee NR, Pi RH, et al. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Arch Pharm Res. 2015;38(5):575–584.
   PubMed Web of Science ®Google Scholar
• Sarosiek S, Shah R, Munshi NC. Review of siltuximab in the treatment of multicentric Castleman’s disease. Therapeutic Advances in Hematology. 2016;7(6):360–366.
   PubMed Web of Science ®Google Scholar
• Avci AB, Feist E, Burmester GR. Targeting IL-6 or IL-6 receptor in rheumatoid arthritis: what’s the difference? BioDrugs. 2018;32(6):531–546.
   PubMed Web of Science ®Google Scholar
• Bae S-C, Lee YH. Comparison of the efficacy and tolerability of tocilizumab, sarilumab, and sirukumab in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.Clinical Rheumatology. 2018;37(6):1471–1479.
   PubMed Web of Science ®Google Scholar
• Silpa-Archa S, Oray M, Preble JM, et al. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmologica. 2016;94(6):e400–6.
   PubMed Web of Science ®Google Scholar
• Del Giorno R, Iodice A, Mangas C, et al. New-onset cutaneous sarcoidosis under tocilizumab treatment for giant cell arteritis: a quasi-paradoxical adverse drug reaction. Case report and literature review. Therapeutic Advances in Musculoskeletal Disease. 2019;11:1759720X19841796.
   PubMed Web of Science ®Google Scholar
• Nutz A, Pernet C, Combe B, et al. Sarcoidosis induced by tocilizumab: a paradoxical event? The Journal of Rheumatology. 2013;40(10):1773–1774.
   PubMed Web of Science ®Google Scholar
• Bustamente L, Buscot M, Marquette C-H, et al. Sarcoidosis and tocilizumab: is there a link? Clinical and Experimental Rheumatology. 2017;35(4):716.
   PubMed Web of Science ®Google Scholar
• Shono Y, Kamata M, Takeoka S, et al. Cutaneous sarcoidosis in a patient with rheumatoid arthritis receiving tocilizumab. The Journal of Dermatology. 2018;45(8):e217–e218.
   PubMed Web of Science ®Google Scholar
• Theodosiou G, Luu H, Svensson Å. Tocilizumab-induced sarcoidosis-like reaction in a patient with giant cell arteritis. Clinical implications of a paradoxical phenomenon. International Journal of Dermatology. 2020;59(7):888–889.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Judson MA, Teirstein AS, et al. Thalidomide for chronic sarcoidosis. Chest. 2002;122(1):227–232.
   PubMed Web of Science ®Google Scholar
• Judson MA, Silvestri J, Hartung C, et al. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2006;23(1):51–57.
   PubMed Web of Science ®Google Scholar
• Fazzi P, Manni E, Cristofani R, et al. Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids. Biomedicine & Pharmacotherapy. 2012;66(4):300–307.
   PubMed Web of Science ®Google Scholar
• Droitcourt C, Rybojad M, Porcher R, et al. A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis. Chest. 2014;146(4):1046–1054.
   PubMed Web of Science ®Google Scholar
• Nguyen YT, Dupuy A, Cordoliani F, et al. Treatment of cutaneous sarcoidosis with thalidomide. Journal of the American Academy of Dermatology. 2004;50(2):235–241.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Judson MA, Ingledue R, et al. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Archives of Dermatology. 2012;148(2):262–264.
   PubMedGoogle Scholar
• Zabel P, Entzian P, Dalhoff K, et al. Pentoxifylline in treatment of sarcoidosis.. American Journal of Respiratory and Critical Care Medicine. 1997;155(5):1665–1669.
   PubMed Web of Science ®Google Scholar
• Park MK, Fontana F, Babaali H, et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2009;26(2):121–131.
   PubMed Web of Science ®Google Scholar
• Schweitzer M, Mirsaeidi M, Campos M, et al. Roflumilast Reduces Circulatory IL-17 Levels in Sarcoidosis Subjects with Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017;195:A4754.
   Web of Science ®Google Scholar
• Baughman P, Birring S, Judson MA, et al. A double Blind, Placebo Controlled Study of Roflumilast to Prevent Acute Events in Fibrotic Sarcoidosis. Am J Respiratory Crit Care Med. 2017;195:A4752.
   Web of Science ®Google Scholar
• Wu JJ, Huang DB, Pang KR, et al. Thalidomide: dermatological indications, mechanisms of action and side-effects. British Journal of Dermatology. 2005;153(2):254–273.
   PubMed Web of Science ®Google Scholar
• Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther. 1965;6(3):303–306.
   PubMed Web of Science ®Google Scholar
• Sheskin J. The treatment of lepra reaction in lepromatous leprosy. Fifteen years’ experience with thalidomide. International Journal of Dermatology. 1980;19(6):318–322.
   PubMed Web of Science ®Google Scholar
• Tavares JL, Wangoo A, Dilworth P, et al. Thalidomide reduces tumour necrosis factor-α production by human alveolar macrophages. Respiratory Medicine. 1997;91(1):31–39.
   PubMed Web of Science ®Google Scholar
• Barriere H. Cutaneous sarcoidosis. Treatment with thalidomide. Presse Med. 1983;12(15):963.
   PubMed Web of Science ®Google Scholar
• Carlesimo M, Giustini S, Rossi A, et al. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol. 1995;32(5):866–869.
   PubMed Web of Science ®Google Scholar
• Lee JB, Koblenzer PS. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol. 1998;39(5):835–838.
   PubMed Web of Science ®Google Scholar
• Rousseau L, Beylot-Barry M, Doutre MS, et al. Cutaneous sarcoidosis successfully treated with low doses of thalidomide. Archives of Dermatology. 1998;134(8):1045–1046.
   PubMedGoogle Scholar
• Hoyle JC, Newton HB, Katz S. Prognosis of refractory neurosarcoidosis altered by thalidomide: a case report. J Med Case Rep. 2008;2(1):27.
   PubMedGoogle Scholar
• Hammond ER, Kaplin AI, Kerr DA. Thalidomide for acute treatment of neurosarcoidosis. Spinal Cord. 2007;45(12):802–803.
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016–2029.
   PubMed Web of Science ®Google Scholar
• Poole RM, Ballantyne AD. Apremilast: first global approval. Drugs. 2014;74(7):825–837.
   PubMed Web of Science ®Google Scholar
• Katakami Y, Nakao Y, Koizumi T, et al. Regulation of tumour necrosis factor production by mouse peritoneal macrophages: the role of cellular cyclic AMP.. Immunology. 2020;64(4):719–724.
   Google Scholar
• Kunkel SL, Spengler M, May MA, et al. Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. J Biol Chem. 1988;263(11):5380–5384.
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842–855.
   PubMed Web of Science ®Google Scholar
• Schett G, Sloan VS, Stevens RM, et al. Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. Therapeutic Advances in Musculoskeletal Disease. 2010;2(5):271–278.
   PubMedGoogle Scholar
• Samlaska CP, Winfield EA. Pentoxifylline. Journal of the American Academy of Dermatology. 1994;30(4):603–621.
   PubMed Web of Science ®Google Scholar
• van Furth AM, Verhard‐seijmonsbergen EM, van Furth R, et al. Effect of lisofylline and pentoxifylline on the bacterial-stimulated production of TNF-α, IL-1β and IL-10 by human leucocytes. Immunology. 1997;91(2):193–196.
   PubMed Web of Science ®Google Scholar
• Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxofylline. Biochem Biophys Res Commun. 1988;155(3):1230–1236.
   PubMed Web of Science ®Google Scholar
• Tong Z-H, Dai H-P, Chen B-M, et al. [Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline].. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases. 2003;26(7):415–418.
   PubMedGoogle Scholar
• Marques LJ, Zheng L, Poulakis N, et al. Pentoxifylline inhibits tnf- α production from human alveolar macrophages. American Journal of Respiratory and Critical Care Medicine. 1999;159(2):508–511.
   PubMed Web of Science ®Google Scholar
• Korber M, Kamp S, Kothe H, et al. [Pentoxifylline inhibits secretion of O2- and TNF-alpha by alveolar macrophages in patients with sarcoidosis]. Immunitat und Infektion. 1995;23(3):107–110.
   PubMedGoogle Scholar
• Semmler J, Gebert U, Eisenhut T, et al. Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. Immunology. 1993;78(4):520–525.
   PubMed Web of Science ®Google Scholar
• U.S. National Library of Medicine . daliresp- roflumilast tablet 2020 [updated March 12, 2020; cited 2020 september 7]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9a1d0a8-581f-4f91-a2b8-f419192d0ebf
   Google Scholar
• Gonzalez-Rey E, Delgado M. Role of vasoactive intestinal peptide in inflammation and autoimmunity. Current Opinion in Investigational Drugs (London, England : 2000). 2011;17(2):491–502.
   Google Scholar
• Delgado M, Abad C, Martinez C, et al. Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. Journal of Molecular Medicine. 2017;Volume11(1):16–24.
   Google Scholar
• Delgado M, Chorny A, Gonzalez-Rey E, et al. Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo. J Leukoc Biol. 2005;78(6):1327–1338.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rey E, Fernandez-Martin A, Chorny A, et al. Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis. Arthritis Rheum. 2018;32(6):531–546.
   Google Scholar
• Croxford AL, Kulig P, Becher B. IL-12-and IL-23 in health and disease. Cytokine Growth Factor Rev. 2014;25(4):415–421.
   PubMed Web of Science ®Google Scholar
• Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003;421(6924):744–748.
   PubMed Web of Science ®Google Scholar
• Presky DH, Yang H, Minetti LJ, et al. A functional interleukin 12 receptor complex is composed of two -type cytokine receptor subunits. Proc Natl Acad Sci U S A. 2020;59(7):888–889.
   Google Scholar
• Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715–725.
   PubMed Web of Science ®Google Scholar
• Macatonia SE, Hosken NA, Litton M, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol. 2004;50(2):235–241.
   Google Scholar
• Khader SA, Thirunavukkarasu S. The Tale of IL-12 and IL-23: a Paradigm Shift. J Immunol. 2019;202(3):629–630.
   PubMed Web of Science ®Google Scholar
• Shigehara K, Shijubo N, Ohmichi M, et al. Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis. Clin Exp Immunol. 2005;153(2):254–257.
   Google Scholar
• Hata M, Sugisaki K, Miyazaki E, et al. Circulating IL-12 p40 is increased in the patients with sarcoidosis, correlation with clinical markers. Intern Med. 2007;46(17):1387–1394.
   PubMed Web of Science ®Google Scholar
• Ten Berge B, Paats MS, Bergen IM, et al. Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology (Oxford). 2012;51(1):37–46.
   PubMed Web of Science ®Google Scholar
• Richmond BW, Ploetze K, Isom J, et al. Sarcoidosis Th17 cells are ESAT-6 antigen specific but demonstrate reduced IFN-γ expression. J Clin Immunol. 2013;33(2):446–455.
   PubMed Web of Science ®Google Scholar
• US National Library of Medicine. Stelara (ustekinumab) injection, solution (ssen Biotech, Inc.) 2020 [updated August 4, 2020; cited 2020 September 7]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c77a9664-e3bb-4023-b400-127aa53bca2b#S14.5
   Google Scholar
• Monast CS, Li K, Judson MA, et al. Sarcoidosis extent relates to molecular variability. Clin Exp Immunol. 2017;188(3):444–454.
   PubMed Web of Science ®Google Scholar
• Guo H, Callaway JB, Ting JP-Y. Inflammasomes: mechanism of action, role in disease, and therapeutics. . Nature Medicine. 2015;21(7):677–687.
   PubMed Web of Science ®Google Scholar
• Lamkanfi M, Dixit VM. Inflammasomes and their roles in health and disease. Annual Review of Cell and Developmental Biology. 2012;28(1):137–161.
   PubMedGoogle Scholar
• Xue Y, Enosi Tuipulotu D, Tan WH, et al. Emerging activators and regulators of inflammasomes and pyroptosis. Trends in Immunology. 2019;40(11):1035–1052.
   PubMed Web of Science ®Google Scholar
• Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell. 2014;157(5):1013–1022.
   PubMed Web of Science ®Google Scholar
• Lu F, Lan Z, Xin Z, et al. Emerging insights into molecular mechanisms underlying pyroptosis and functions of inflammasomes in diseases. Journal of Cellular Physiology. 2020;235(4):3207–3221.
   PubMed Web of Science ®Google Scholar
• Abbate A, Toldo S, Marchetti C, et al. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ Res. 2020;126(9):1260–1280.
   PubMed Web of Science ®Google Scholar
• Buckley LF, Abbate A. Interleukin-1 blockade in cardiovascular diseases: a clinical update. Eur Heart J. 2018;39(22):2063–2069.
   PubMed Web of Science ®Google Scholar
• Huppertz C, Jäger B, Wieczorek G, et al. The NLRP3 inflammasome pathway is activated in sarcoidosis and involved in granuloma formation. European Respiratory Journal. 2020;55(3):1900119.
   PubMed Web of Science ®Google Scholar
• Fireman E, Aderka D, Efraim SB, et al. Suppressive effect of TNF-α and IL-1 on alveolar fibroblast proliferation in sarcoidosis. Mediators Inflamm. 1992;1(5):319–322.
   PubMedGoogle Scholar
• Terao I, Hashimoto S, Horie T. Effect of GM-CSF on TNF-alpha and IL-1-beta production by alveolar macrophages and peripheral blood monocytes from patients with sarcoidosis. Int Arch Allergy Immunol. 1993;102(3):242–248.
   PubMed Web of Science ®Google Scholar
• Kasahara K, Kobayashi K, Shikama Y, et al. Direct evidence for granuloma-inducing activity of interleukin-1. Induction of experimental pulmonary granuloma formation in mice by interleukin-1-coupled beads.. The American Journal of Pathology. 1988;130(3):629–638.
   PubMed Web of Science ®Google Scholar
• Kron J, Mauro AG, Bonaventura A, et al. Inflammasome formation in granulomas in cardiac sarcoidosis. Circ Arrhythm Electrophysiol. 2019;12(9):e007582.
   PubMed Web of Science ®Google Scholar
• Abbate A, Trankle CR, Buckley LF, et al. Interleukin-1 blockade inhibits the acute inflammatory response in patients with st-segment–elevation myocardial infarction. J Am Heart Assoc. 2020;9(5):e014941.
   PubMed Web of Science ®Google Scholar
• Wohlford GF, Buckley LF, Vecchie A, et al. Acute effects of interleukin-1 blockade using anakinra in patients with acute pericarditis. J Cardiovasc Pharmacol. 2020;76(1):50–52.
   PubMed Web of Science ®Google Scholar
• Buckley LF, Viscusi MM, Van Tassell BW, et al. Interleukin-1 blockade for the treatment of pericarditis. Eur Heart J Cardiovasc Pharmacother. 2018;4(1):46–53.
   PubMed Web of Science ®Google Scholar
• Van Tassell BW, Abouzaki NA, Oddi Erdle C, et al. Interleukin-1 Blockade in Acute Decompensated Heart Failure. J Cardiovasc Pharmacol. 2003;26(7):415–418.
   Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119–1131.
   PubMed Web of Science ®Google Scholar
• Furst DE, Keystone EC, Fleischmann R, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis. 2010;69(Suppl 1):i2–29.
   PubMed Web of Science ®Google Scholar
• Feist E, Burmester GR. Canakinumab for treatment of cryopyrin-associated periodic syndrome. Expert Opin Biol Ther. 2010;10(11):1631–1636.
   PubMed Web of Science ®Google Scholar
• So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010;62(10):3064–3076.
   PubMed Web of Science ®Google Scholar
• US National Library of Medicine. Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis 2016 [updated March 16, 2020; cited 2020 September 21]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02888080
   Google Scholar
• US National Library of Medicine. Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis (MAGiC-ART): US National Library of Medicine; 2019 [updated September 1 2020; cited 2020 September 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT04017936?term=anakinra&cond=Sarcoidosis&cntry=US&draw=2&rank=1
   Google Scholar
• Sacre K, Pasqualoni E, Descamps V, et al. Sarcoid-like granulomatosis in a patient treated by interleukin-1 receptor antagonist for TNF-receptor-associated periodic syndrome. Rheumatology (Oxford). 2013;52(7):1338–1340.
   PubMed Web of Science ®Google Scholar
• Friedman BE, English JC. Drug-induced sarcoidosis in a patient treated with an interleukin-1 receptor antagonist for hidradenitis suppurativa. JAAD Case Rep. 2018;4(6):543–545.
   PubMedGoogle Scholar
• Yasuda K, Nakanishi K, Tsutsui H. Interleukin-18 in Health and Disease. Int J Mol Sci. 2019;20(3):649.
   Web of Science ®Google Scholar
• Greene CM, Meachery G, Taggart CC, et al. Role of IL-18 in CD4+ T lymphocyte activation in sarcoidosis. J Immunol. 2000;165(8):4718–4724.
   PubMed Web of Science ®Google Scholar
• Kieszko R, Krawczyk P, kowska O, et al. The clinical significance of interleukin 18 assessment in sarcoidosis patients. Respir Med. 2007;101(4):722–728.
   PubMed Web of Science ®Google Scholar
• Antoniou KM, Tzouvelekis A, Alexandrakis MG, et al. Upregulation of Th1 cytokine profile (IL-12, IL-18) in bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. J Interferon Cytokine Res. 2006;26(6):400–405.
   PubMed Web of Science ®Google Scholar
• Mroz RM, Korniluk M, Stasiak-Barmuta A, et al. Increased levels of interleukin-12 and interleukin-18 in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. J Physiol Pharmacol. 2008;59(Suppl 6):507–513.
   PubMedGoogle Scholar
• Shigehara K, Shijubo N, Ohmichi M, et al. Increased levels of interleukin-18 in patients with pulmonary sarcoidosis. Am J Respir Crit Care Med. 2000;162(5):1979–1982.
   PubMed Web of Science ®Google Scholar
• Ruderman EM, Pope RM. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Arthritis Res Ther. 2005;7(Suppl 2):S21–5.
   PubMedGoogle Scholar
• Chambers CA, Kuhns MS, Egen JG, et al. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001;19:565–594.
   PubMed Web of Science ®Google Scholar
• Qureshi OS, Zheng Y, Nakamura K, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332(6029):600–603.
   PubMed Web of Science ®Google Scholar
• Broos CE, van Nimwegen M, In ‘T Veen JC, et al. reased Cytotoxic T-Lymphocyte Antigen 4 Expression on Regulatory T Cells and Th17 Cells in Sarcoidosis: double Trouble? Am J Respir Crit Care Med. 2015;192(6):763–765.
   PubMed Web of Science ®Google Scholar
• Hattori N, Niimi T, Sato S, et al. Cytotoxic T-lymphocyte antigen 4 gene polymorphisms in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(1):27–32.
   PubMed Web of Science ®Google Scholar
• Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211.
   PubMed Web of Science ®Google Scholar
• Reddy SB, Possick JD, Kluger HM, et al. Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma. J Immunother. 2017;40(8):307–311.
   PubMed Web of Science ®Google Scholar
• Kuehn HS, Ouyang W, Lo B, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014;345(6204):1623–1627.
   PubMed Web of Science ®Google Scholar
• Schubert D, Bode C, Kenefeck R, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20(12):1410–1416.
   PubMed Web of Science ®Google Scholar
• Zeissig S, Petersen BS, Tomczak M, et al. Early-onset Crohn’s disease and autoimmunity associated with a variant in CTLA-4. Gut. 2015;64(12):1889–1897.
   PubMed Web of Science ®Google Scholar
• Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991;174(3):561–569.
   PubMed Web of Science ®Google Scholar
• Brown S, Everett CC, Naraghi K, et al. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Health Technol Assess. 2018;22(34):1–280.
   Web of Science ®Google Scholar
• Buch MH, Vital EM, Emery P. Abatacept in the treatment of rheumatoid arthritis. Arthritis Res Ther. 2008;10(Suppl 1):S5.
   PubMedGoogle Scholar
• Frye BC, Rump IC, Uhlmann A, et al. Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) - protocol for a multi-center, single-arm phase IIa trial. Contemp Clin Trials Commun. 2020;19:100575.
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P, Lampaki S, Turner JF, et al. mTOR pathway: a current, up-to-date mini-review (Review). Oncol Lett. 2014;8(6):2367–2370.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–293.
   PubMed Web of Science ®Google Scholar
• Hua H, Kong Q, Zhang H, et al. Targeting mTOR for cancer therapy. J Hematol Oncol. 2019;12(1):71.
   PubMed Web of Science ®Google Scholar
• Pacheco Y, Lim CX, Weichhart T, et al. Sarcoidosis and the mTOR, Rac1, and Autophagy Triad. Trends Immunol. 2020;41(4):286–299.
   PubMed Web of Science ®Google Scholar
• Linke M, Pham HT, Katholnig K, et al. Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat Immunol. 2017;18(3):293–302.
   PubMed Web of Science ®Google Scholar
• Calender A, Lim CX, Weichhart T, et al. Exome sequencing and pathogenicity-network analysis of 5 French families implicate mTOR signalling and autophagy in familial sarcoidosis. Eur Respir J. 2019;54(2):190043.
   PubMed Web of Science ®Google Scholar
• Crouser ED, Locke LW, Julian MW, et al. Phagosome-regulated mTOR Signalling during Sarcoidosis Granuloma Biogenesis. Eur Respir J. 2020;Sep17:2002695.
   Web of Science ®Google Scholar
• Li J, Kim SG, Blenis J. Rapamycin: one drug, many effects. Cell Metab. 2014;19(3):373–379.
   PubMed Web of Science ®Google Scholar
• Benjamin D, Colombi M, Moroni C, et al. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov. 2011;10(11):868–880.
   PubMed Web of Science ®Google Scholar
• Gupta N, Bleesing JH, McCormack FX. Successful Response to Treatment with Sirolimus in Pulmonary Sarcoidosis. Am J Respir Crit Care Med. 2020;202(9):e119-120.
   Web of Science ®Google Scholar
• Manzia TM, Bellini MI, Corona L, et al. Successful treatment of systemic de novo sarcoidosis with cyclosporine discontinuation and provision of rapamune after liver transplantation. Transpl Int. 2011;24(8):e69–70.
   PubMed Web of Science ®Google Scholar
• Cabahug VLO, Uy HS, Yu-Keh E, et al. Outcomes of treatment with sirolimus for non-infectious uveitis: a meta-analysis and systematic review. Clin Ophthalmol. 2019;13:649–669.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Ibrahim MA, Watters A, et al. Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect. 2013;3(1):32.
   PubMedGoogle Scholar
• Ibrahim MA, Sepah YJ, Watters A, et al. One-Year Outcomes of the SAVE Study: sirolimus as a Therapeutic Approach for UVEitis. Transl Vis Sci Technol. 2015;4(2):4.
   PubMed Web of Science ®Google Scholar
• Merrill PT, Clark WL, Banker AS, et al. Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program. Ophthalmology. 2020;127(10):1405–1415.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Clark WL, et al. Intravitreal sirolimus for noninfectious uveitis: a phase iii sirolimus study assessing double-masked uveitis treatment (SAKURA). Ophthalmology. 2016;123(11):2413–2423.
   PubMed Web of Science ®Google Scholar
• Kirk SG, Samavati L, Liu Y. MAP kinase phosphatase-1, a gatekeeper of the acute innate immune response. Life Sci. 2020;241:117157.
   PubMed Web of Science ®Google Scholar
• Rastogi R, Du W, Ju D, et al. Dysregulation of p38 and MKP-1 in response to NOD1/TLR4 stimulation in sarcoid bronchoalveolar cells. Am J Respir Crit Care Med. 2011;183(4):500–510.
   PubMed Web of Science ®Google Scholar
• Kyttaris VC. Kinase inhibitors: a new class of antirheumatic drugs. Drug Des Devel Ther. 2012;6:245–250.
   PubMed Web of Science ®Google Scholar
• Alten RE, Zerbini C, Jeka S, et al. Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. Ann Rheum Dis. 2010;69(2):364–367.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Cheng TT, Chindalore V, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum. 2009;60(2):335–344.
   PubMed Web of Science ®Google Scholar
• Damov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 ;60(5):1232–1241.
   PubMedGoogle Scholar
• Genovese MC, Cohen SB, Wofsy D, et al. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol. 2011 ;38(5):846–854.
   PubMed Web of Science ®Google Scholar
• Dotan I, Rachmilewitz D, Schreiber S, et al. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn’s disease. Gut. 2010;59(6):760–766.
   PubMed Web of Science ®Google Scholar
• Valeyre D, Soler P, Clerici C, et al. Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease. Thorax. 1988;43(7):516–524.
   PubMed Web of Science ®Google Scholar
• Harf RA, Ethevenaux C, Gleize J, et al. Reduced prevalence of smokers in sarcoidosis. Results of a case-control study. Ann N Y Acad Sci. 1986;465:625–631.
   PubMed Web of Science ®Google Scholar
• Parrish WR, Rosas-Ballina M, Gallowitsch-Puerta M, et al. Modulation of TNF release by choline requires alpha7 subunit nicotinic acetylcholine receptor-mediated signaling. Mol Med. 2008;14(9–10):567–574.
   PubMed Web of Science ®Google Scholar
• Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature. 2003;421(6921):384–388.
   PubMed Web of Science ®Google Scholar
• Nizri E, Irony-Tur-Sinai M, Lory O, et al. Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses. J Immunol. 2009;183(10):6681–6688.
   PubMed Web of Science ®Google Scholar
• Sopori ML, Kozak W, Savage SM, et al. Effect of nicotine on the immune system: possible regulation of immune responses by central and peripheral mechanisms. Psychoneuroendocrinology. 1998;23(2):189–204.
   PubMed Web of Science ®Google Scholar
• Marrero MB, Bencherif M. Convergence of alpha 7 nicotinic acetylcholine receptor-activated pathways for anti-apoptosis and anti-inflammation: central role for JAK2 activation of STAT3 and NF-kappaB. Brain Res. 2009;1256:1–7.
   PubMed Web of Science ®Google Scholar
• Wang DW, Zhou RB, Yao YM, et al. Stimulation of alpha7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro. J Pharmacol Exp Ther. 2010;335(3):553–561.
   PubMed Web of Science ®Google Scholar
• Geng Y, Savage SM, Johnson LJ, et al. Effects of nicotine on the immune response. I. Chronic exposure to nicotine impairs antigen receptor-mediated signal transduction in lymphocytes. Toxicol Appl Pharmacol. 1995;135(2):268–278.
   PubMed Web of Science ®Google Scholar
• Yoshikawa H, Kurokawa M, Ozaki N, et al. Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-kappaB phosphorylation and nuclear factor-kappaB transcriptional activity through nicotinic acetylcholine receptor alpha7. Clin Exp Immunol. 2006;146(1):116–123.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zuo X, Li Y, et al. Nicotine inhibits tumor necrosis factor-alpha induced IL-6 and IL-8 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Rheumatol Int. 2012;32(1):97–104.
   PubMed Web of Science ®Google Scholar
• Julian MW, Shao G, Schlesinger LS, et al. Nicotine treatment improves Toll-like receptor 2 and Toll-like receptor 9 responsiveness in active pulmonary sarcoidosis. Chest. 2013;143(2):461–470.
   PubMed Web of Science ®Google Scholar
• Nemeth K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009;15(1):42–49.
   PubMed Web of Science ®Google Scholar
• Chiossone L, Conte R, Spaggiari GM, et al. Mesenchymal stromal cells induce peculiar alternatively activated macrophages capable of dampening both innate and adaptive immune responses. Stem Cells. 2016;34(7):1909–1921.
   PubMed Web of Science ®Google Scholar
• Stagg J, Galipeau J. Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation. Curr Mol Med. 2013;13(5):856–867.
   PubMed Web of Science ®Google Scholar
• Vasandan AB, Jahnavi S, Shashank C, et al. Human Mesenchymal stem cells program macrophage plasticity by altering their metabolic status via a PGE2-dependent mechanism. Sci Rep. 2016;6:38308.
   PubMed Web of Science ®Google Scholar
• Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood. 2005;105(5):2214–2219.
   PubMed Web of Science ®Google Scholar
• Gur-Wahnon D, Borovsky Z, Beyth S, et al. Contact-dependent induction of regulatory antigen-presenting cells by human mesenchymal stem cells is mediated via STAT3 signaling. Exp Hematol. 2007;35(3):426–433.
   PubMed Web of Science ®Google Scholar
• Bernardo ME, Fibbe WE. Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders. Ann N Y Acad Sci. 2012;1266:107–117.
   PubMed Web of Science ®Google Scholar
• Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7(10):e47559.
   PubMed Web of Science ®Google Scholar
• Reinders ME, Dreyer GJ, Bank JR, et al. Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study. J Transl Med. 2015;13:344.
   PubMed Web of Science ®Google Scholar
• Knyazev OV, Parfenov AI, Konoplyannikov AG, et al. [Safety of mesenchymal stromal cell therapy for inflammatory bowel diseases: results of a 5-year follow-up]. Ter Arkh. 2015;87(2):39–44.
   PubMed Web of Science ®Google Scholar
• Zhao R, Su Z, Wu J, et al. Serious adverse events of cell therapy for respiratory diseases: a systematic review and meta-analysis. Oncotarget. 2017;8(18):30511–30523.
   PubMedGoogle Scholar
• Baughman RP, Culver DA, kovi V, et al. Placenta-derived mesenchymal-like cells (PDA-001) as therapy for chronic pulmonary sarcoidosis: a phase 1 study. Sarcoidosis Vasc Diffuse Lung Dis. 2015;32(2):106–114.
   PubMed Web of Science ®Google Scholar
• McClain Caldwell I, Hogden C, Nemeth K, et al. Bone Marrow-Derived Mesenchymal Stromal Cells (MSCs) Modulate the Inflammatory Character of Alveolar Macrophages from Sarcoidosis Patients. J Clin Med. 2020;9(1):278.
   PubMed Web of Science ®Google Scholar
• Ginoux E, Kottler D, Anglaret B, et al. Remission of a long-lasting sarcoidosis after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. JAAD Case Rep. 2016;2(5):408–410.
   PubMedGoogle Scholar
• Tauro S, Mahendra P. Resolution of sarcoidosis after allogeneic bone marrow transplantation with donor lymphocyte infusions. Bone Marrow Transplant. 2001;27(7):757–759.
   PubMed Web of Science ®Google Scholar
• Bhagat R, Rizzieri DA, Vredenburgh JJ, et al. Pulmonary sarcoidosis following stem cell transplantation: is it more than a chance occurrence? Chest. 2004;126(2):642–644.
   PubMed Web of Science ®Google Scholar
• Gooneratne L, Lim ZY, Vivier A, et al. Sarcoidosis as an unusual cause of hepatic dysfunction following reduced intensity conditioned allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;39(8):511–512.
   PubMed Web of Science ®Google Scholar
• Kushima H, Ishii H, Ikewaki J, et al. Sarcoidosis in donor-derived tissues after haematopoietic stem cell transplantation. Eur Respir J. 2013;41(6):1452–1453.
   PubMed Web of Science ®Google Scholar
• Marchal A, Charlotte F, Maksud P, et al. [Sarcoidosis flare after autologous stem cell transplantation: an immune paradox?]. Rev Med Interne. 2017;38(9):619–622.
   PubMed Web of Science ®Google Scholar
• Teo M, McCarthy JE, Brady AP, et al. A case of sarcoidosis in a patient with testicular cancer post stem cell transplant. Acta Oncol. 2013;52(4):869–871.
   PubMed Web of Science ®Google Scholar
• Marks PW, Witten CM, Califf RM. Clarifying Stem-Cell Therapy’s Benefits and Risks. N Engl J Med. 2017;376(11):1007–1009.
   PubMed Web of Science ®Google Scholar
• FDA Warns About Stem Cell Therapies 2017 [ updated 09/03/2019 cited 2020 September 24]. https://www.fda.gov/consumers/consumer-updates/fda-warns-about-stem-cell-therapies
   Google Scholar